journal article·2022-12-12

SARS-CoV-2 Spike Protein-Activated Dendritic Cell-Derived Extracellular Vesicles Induce Antiviral Immunity in Mice

Anjali Barnwal, Brohmomoy Basu, Aarti Tripathi, Naina Soni, Debasish Mishra, Arup Banerjee, Rajesh Kumar, Sudhanshu Vrati, Jayanta Bhattacharyya

Publisher page

Abstract

The onset and spread of the SARS-CoV-2 virus have created an unprecedented universal crisis. Although vaccines have been developed against the parental SARS-CoV-2, outbreaks of the disease still occur through the appearance of different variants, suggesting a continuous need for improved and effective therapeutic strategies. Therefore, we developed a novel nanovesicle presenting Spike protein on the surface of the dendritic cell-derived extracellular vesicles (DEVs) for use as a potential vaccine platform against SARS-CoV-2. DEVs express peptide/MHC-I (pMHC-I) complexes, CCR-7, on their surface. The immunogenicity and efficacy of the Spike-activated DEVs were tested in mice and compared with free Spike protein. A 1/10 Spike equivalent dose of DEVs showed a superior potency in inducing anti-Spike IgG titers in blood of mice when compared to dendritic cells or free Spike protein treatment. Moreover, DEV-induced sera effectively reduced viral infection by 55–60% within 15 days of booster dose administration. Furthermore, a 1/10 Spike equivalent dose of DEV-treated mice was found to be equally effective in inducing CD19+CD38+ T-cells in the spleen and lymph node; CD8 cells in the bone marrow, spleen, and lymph node; and CD4+CD25+ T-cells in the spleen and lymph node after 90 days of treatment. Thus, our results support the immunogenic nature of DEVs, demonstrating that a low dose of DEVs induces antibodies to inhibit SARS-CoV-2 infection in vitro, therefore warranting further investigations.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · SARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India

Department of Biomedical Engineering, All India Institute of Medical Science, New Delhi 110029, India

Laboratory of Virology, Regional Centre for Biotechnology, Faridabad 121001, Haryana, India

Translational Health Science & Technology Institute, Faridabad 121001, Haryana, India

Funding

Indian Council of Medical Research · Science and Engineering Research Board · Department of Biotechnology , Ministry of Science and Technology · Indian Institute of Technology Delhi

References (49)

Show source-provided references
1. 10.1038/s41541-020-0188-310.1038/s41541-020-0188-3 ↗
2. 10.1002/adma.20200563710.1002/adma.202005637 ↗
3. 10.1002/adma.20210778110.1002/adma.202107781 ↗
4. 10.1002/adma.20210252810.1002/adma.202102528 ↗
5. 10.1002/adma.20210436210.1002/adma.202104362 ↗
6. 10.1172/JCI8113710.1172/JCI81137 ↗
7. 10.1093/annonc/mdh91810.1093/annonc/mdh918 ↗
8. 10.1182/blood.V100.5.1734.h81702001734_1734_174110.1182/blood.V100.5.1734.h81702001734_1734_1741 ↗
9. 10.1084/jem.185.12.213310.1084/jem.185.12.2133 ↗
10. 10.4049/jimmunol.163.12.646210.4049/jimmunol.163.12.6462 ↗
11. 10.4049/jimmunol.164.6.309510.4049/jimmunol.164.6.3095 ↗
12. 10.1038/s41467-020-14344-710.1038/s41467-020-14344-7 ↗
13. 10.1016/j.apsb.2016.02.00110.1016/j.apsb.2016.02.001 ↗
14. 10.1016/j.semcancer.2022.04.00510.1016/j.semcancer.2022.04.005 ↗
15. 10.1016/j.micinf.2007.07.00210.1016/j.micinf.2007.07.002 ↗
16. 10.4049/jimmunol.179.8.502410.4049/jimmunol.179.8.5024 ↗
17. 10.4049/jimmunol.210063710.4049/jimmunol.2100637 ↗
18. 10.3390/v1402032910.3390/v14020329 ↗
19. 10.1016/j.immuni.2020.05.00210.1016/j.immuni.2020.05.002 ↗
20. 10.3389/fimmu.2021.73110010.3389/fimmu.2021.731100 ↗
21. 10.1186/s12876-021-02056-110.1186/s12876-021-02056-1 ↗
22. 10.1016/j.jinf.2020.03.05410.1016/j.jinf.2020.03.054 ↗
23. 10.1146/annurev-immunol-042718-04171710.1146/annurev-immunol-042718-041717 ↗
24. 10.1371/journal.pone.017994210.1371/journal.pone.0179942 ↗
25. 10.1182/blood-2006-01-017710.1182/blood-2006-01-0177 ↗
26. 10.1146/annurev-immunol-031210-10140010.1146/annurev-immunol-031210-101400 ↗
27. 10.1002/jev2.1219210.1002/jev2.12192 ↗
28. 10.1016/j.omtm.2022.01.01510.1016/j.omtm.2022.01.015 ↗
29. 10.1038/s41467-022-28446-x10.1038/s41467-022-28446-x ↗
30. 10.1038/s41577-020-00471-110.1038/s41577-020-00471-1 ↗
31. 10.1038/s41598-021-00765-x10.1038/s41598-021-00765-x ↗
32. 10.3389/fmicb.2018.0179210.3389/fmicb.2018.01792 ↗
33. 10.1073/pnas.100062110710.1073/pnas.1000621107 ↗
34. 10.1371/journal.ppat.100606410.1371/journal.ppat.1006064 ↗
35. 10.1038/srep2013710.1038/srep20137 ↗
36. 10.1007/s00430-015-0447-510.1007/s00430-015-0447-5 ↗
37. 10.1016/j.immuni.2013.02.02010.1016/j.immuni.2013.02.020 ↗
38. 10.1038/nri315210.1038/nri3152 ↗
39. 10.1016/j.immuni.2019.04.01110.1016/j.immuni.2019.04.011 ↗
40. 10.3389/fimmu.2021.74070810.3389/fimmu.2021.740708 ↗
41. 10.4049/jimmunol.149001910.4049/jimmunol.1490019 ↗
42. 10.1016/j.bbamcr.2014.05.01410.1016/j.bbamcr.2014.05.014 ↗
43. 10.1016/j.cytogfr.2020.06.00110.1016/j.cytogfr.2020.06.001 ↗
44. 10.1016/j.biopha.2020.11069810.1016/j.biopha.2020.110698 ↗
45. 10.1016/j.jinf.2020.06.00810.1016/j.jinf.2020.06.008 ↗
46. 10.1016/j.omtm.2019.12.00310.1016/j.omtm.2019.12.003 ↗
47. 10.1074/jbc.AC120.01491810.1074/jbc.AC120.014918 ↗
48. 10.1016/j.intimp.2021.10802010.1016/j.intimp.2021.108020 ↗
49. 10.1101/2020.03.02.97293510.1101/2020.03.02.972935 ↗